Has Tavell Kindall received payments from drug or device companies?

Yes. Drug and device makers reported $194,017 in general payments to Tavell Kindall across 433 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tavell Kindall did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tavell Kindall come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tavell Kindall

Family · New Orleans, LANPI 1124379375

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 73.0% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $62,780, 4.1 times the $15,139 reported in 2021. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$194,017in general payments, 2019–2025

Across 433 payments — averaging $448.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$142K
Viiv Healthcare Company$45K
Janssen Products, LP$5K
Janssen Scientific Affairs, LLC$1K
AbbVie$212
Theratechnologies Inc.$173
plus $460 from 5 others

What the payments were for

Consulting fees$48,86525%
Speaking & faculty fees$98,15251%
Travel & lodging$36,23319%
Food & beverage$10,5095%
Education$2590%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	272	$141,626
Viiv Healthcare Company	129	$45,104
Janssen Products, LP	14	$5,209
Janssen Scientific Affairs, LLC	2	$1,232
AbbVie	4	$212
Theratechnologies Inc.	2	$173
Abbott	1	$128
Pharmacyclics LLC, An Abbvie Company	1	$123
Neurocrine Biosciences, Inc.	1	$94
Johnson & Johnson	6	$89
Mayne Pharma Commercial LLC	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Descovy$42,164
Biktarvy$38,187
DOVATO$36,118
Yeztugo$15,473
Symtuza$6,110
CABENUVA$230
FreeStyle Libre 2$128
IMBRUVICA$123
Epclusa$122
LINZESS$118
EGRIFTA SV$106

How this compares

$194,017 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	116	$458,433
JulucaDolutegravir/Rilpivirine	33	$124,320
DovatoDolutegravir Sodium/Lamivudine	27	$79,693
TivicayDolutegravir Sodium	25	$58,130
DescovyEmtricitabine/Tenofov Alafenam	19	$42,020
VemlidyTenofovir Alafenamide	12	$16,261
ValacyclovirValacyclovir Hcl	11	$773
Gabapentin	12	$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GileadBiktarvy, Descovy, Vemlidy	$141,626	$516,714147 claims
Viiv Healthcare CompanyJuluca, Dovato, Tivicay	$45,104	$262,14385 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in New Orleans

Erin PierceNew Orleans$261K
Amy SchmittNew Orleans$48K
Eric BabineauxNew Orleans$32K
Cherie AlbroNew Orleans$29K
Aimee ScroggsNew Orleans$20K
Kelly BaquetNew Orleans$18K
Lori LemoineNew Orleans$17K
Jennifer GreenheckNew Orleans$15K
Joseph DefraitesNew Orleans$13K
Rebecca EzellSlidell$268K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →